← Back to all trials
Completed
NCT05720221
Biologics in Management of Inflammatory Bowel Disease in Egyptian Patients
Conditions: IBD
Sex: All
Ages: 18 Years – 65 Years
Enrollment: 100
Sponsor: Helwan University
Location: Egypt
Summary
Inflammatory bowel disease (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), is a chronic inflammatory relapsing disorder affecting the gastrointestinal tract and is characterized by a progressive and unpredictable disease course.The two goals of therapy are the achievement of remission (induction) and the prevention of disease flares (maintenance).
Medical therapy for IBD has advanced dramatically in the last decade with the introduction of targeted biologic therapies including infliximab,adalimumab and ustekinumab.There is paucity of head-to-head studies comparing the effectiveness of ustekinumab and adalimumab in inflammatory bowel disease patients especially in Egyptian population which prompted this study to be conducted.
Eligibility Criteria
Inclusion Criteria:Age:18 year old or more.Gender: both male and female patients.Patients with IBD diagnosis established by clinical, laboratory and endoscopic findings.Moderate to severe inflammatory bowel disease patients.Exclusion Criteria:Age less than 18 years.Malignancy.Pregnant women.
Source: ClinicalTrials.gov (NCT05720221). StuddyBuddy aggregates publicly available trial information.
